Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Vibecortamab Combined With Putilimab in Locally Advanced Laryngeal Cancer
NCT07538206Phase 2Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Apr 2026
- Primary completion
- Apr 2031
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of vibecotamab, pucotenlimab in laryngeal cancer, sponsored by Tangdu Hospital. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
vibecotamabpucotenlimab
03
Conditions
laryngeal cancer
Beyond the preview
Go deeper on NCT07538206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07538206.